Informations générales
  • Catégorie de maladie Maladies de l'œil (BASEC)
  • État du recrutement recrutement terminé (BASEC/ICTRP)
  • Lieu de l’étude
    Bâle
    (BASEC)
  • Responsable de l'étude Maximilian Pfau maximilian.pfau@iob.ch (BASEC)
  • Source(s) de données BASEC: Importé de 11.07.2025 ICTRP: N/A
  • Date de mise à jour 11.07.2025 10:55
HumRes63145 | SNCTP000005621 | BASEC2023-D0049

Clinical examination of a new medical device (MAIA) for conducting visual field tests (microperimetry) compared to the established MAIA-2013 device

  • Catégorie de maladie Maladies de l'œil (BASEC)
  • État du recrutement recrutement terminé (BASEC/ICTRP)
  • Lieu de l’étude
    Bâle
    (BASEC)
  • Responsable de l'étude Maximilian Pfau maximilian.pfau@iob.ch (BASEC)
  • Source(s) de données BASEC: Importé de 11.07.2025 ICTRP: N/A
  • Date de mise à jour 11.07.2025 10:55

Résumé de l'étude

The overarching purpose of this study is to characterize the new MAIA perimeter for visual field examination (microperimetry). Study objectives: 1. To ensure that the visual field measurements are accurate, it will be evaluated whether the measurement results are comparable to those of the established MAIA-2013 device (validity). 2. Additionally, the visual field examination will be repeated on both devices to assess the repeatability for the new device (retest reliability). Procedure: First, a brief ophthalmological routine examination will be conducted, including the assessment of visual acuity, determination of intraocular pressure, and imaging of the retina (SD-OCT). During the visual field examination, weak light points of varying brightness will be presented. By pressing a response button, participants can determine the perception threshold for different locations in the visual field. A total of four visual field examinations will be conducted: two with the new device, two with the established device.

(BASEC)

Intervention étudiée

Visual field examination with the MAIA (validity compared to the gold standard and repeatability)

(BASEC)

Maladie en cours d'investigation

Healthy subjects and patients with retinal diseases

(BASEC)

Critères de participation
Inclusion criteria for the group of healthy subjects 1. Age: 18-90 years; 2. Best corrected visual acuity (BCVA): ≥ 0.8 decimal (20/25 ft, +0.1 LogMAR) at least in the study eye; 3. Spherical equivalent between -12 dpt and +6 dpt; astigmatism less than 2 dpt at least in the study eye; 4. Intraocular pressure (IOD) ≤ 21 mmHg in both eyes (Goldmann applanation tonometer); 5. Clinically normal appearance of the optic nerve head (no signs of increased excavation, rim thinning, notches, disc margin hemorrhages, RNFL thinning) in both eyes. This will be examined with Spectralis OCT; 6. Clinically normal appearance of the macula, in both eyes. This will be examined with Spectralis OCT; 7. No ocular pathologies, trauma, surgeries (except for an uncomplicated cataract surgery performed at least 6 months prior to study enrollment) in both eyes; 8. Absence of pathologies that may affect the visual field in both eyes; 9. No intake of medications that may affect the proper execution of perimetry. Inclusion criteria for the group of patients with retinal diseases 1. Age: 18-90 years; 2. BCVA: ≥ 0.1 decimal (20/200 ft, +1.0 logmar) at least in the study eye; 3. Spherical equivalent between -12 dpt and +6 dpt; astigmatism less than 2 dpt at least in the study eye; 4. Diagnosis of any type of retinal disease by the investigator based on funduscopy and Spectralis OCT, for which a microperimetry examination is indicated, at least in the study eye. This includes, among others: early and intermediate age-related macular degeneration (AMD), geographic atrophy (GA), neovascular AMD, history of retinal pigment epithelium (RPE)-choroid transplantation, diabetic retinopathy (DR), retinal vascular diseases, pathological myopia, retinal dystrophies, vitreoretinal interface disorders, inflammatory chorioretinal disorders, toxic retinopathies, glaucoma, and others. (BASEC)

Critères d'exclusion
Exclusion criteria for the group of healthy subjects 1. Glaucoma or glaucoma-suspect diagnosis in either eye; 2. Presence or history of ocular hypertension (IOD ≥ 22 mmHg) in either eye; 3. Presence or history of disc margin hemorrhage in either eye; 4. Amblyopia in either eye; 5. Nystagmus or poor fixation in either eye; 6. Previous laser or other eye surgeries, including uncomplicated cataract surgeries, performed within 6 months prior to study enrollment in both eyes; 7. Any active infection of the anterior or posterior segments of the study eye; 8. Subjects with significant media opacities preventing acceptable quality of fundus imaging in the 9th infrared domain (IR) of the study eye; 9. Signs of diabetic retinopathy, diabetic macular edema, or other retinal diseases in either eye; 10. Intake of medications that may affect the proper execution of MP or may lead to visual field losses; 11. Intolerance to ophthalmic imaging; 12. Claustrophobia; 13. Inability to provide informed consent. Exclusion criteria for the group of patients with retinal diseases 1. Any ophthalmic surgery on the study eye. Exception: uncomplicated cataract surgery performed at least 6 months prior to the start of the study; 2. Subjects who cannot tolerate ophthalmic imaging; 3. Nystagmus in either eye; 4. Subjects with significant media opacities preventing acceptable quality of IR fundus images in the study eye; 5. Intake of medications that may affect the proper execution of MP or may lead to visual field losses; 6. Claustrophobia; 7. Inability to provide informed consent; 8. In the investigator's assessment, at-risk subjects (i.e., recent [3 months] or imminent deterioration of vision [3 lines on an ETDRS visual acuity chart]). (BASEC)

Lieu de l’étude

Bâle

(BASEC)

non disponible

Sponsor

Professor Dr. med. Hendrik P.N. Scholl, MA

(BASEC)

Contact pour plus d'informations sur l'étude

Personne de contact en Suisse

Maximilian Pfau

+41 ‪61 568 73 23

maximilian.pfau@iob.ch

Universitätsspital Basel, Augenklinik, Mittlere Strasse 91, CH-4031 Basel, Switzerland

(BASEC)

Informations scientifiques

non disponible

Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)

Ethikkommission Nordwest- und Zentralschweiz EKNZ

(BASEC)

Date d'approbation du comité d'éthique

07.09.2023

(BASEC)


Identifiant de l'essai ICTRP
non disponible

Titre officiel (approuvé par le comité d'éthique)
Pre-market monocentric cross-sectional clinical investigation of MAIA on healthy subjects and patients with retinal pathology: agreement with MAIA 2013 EDITION microperimeter and repeatability evaluation (BASEC)

Titre académique
non disponible

Titre public
non disponible

Maladie en cours d'investigation
non disponible

Intervention étudiée
non disponible

Type d'essai
non disponible

Plan de l'étude
non disponible

Critères d'inclusion/exclusion
non disponible

non disponible

Critères d'évaluation principaux et secondaires
non disponible

non disponible

Date d'enregistrement
non disponible

Inclusion du premier participant
non disponible

Sponsors secondaires
non disponible

Contacts supplémentaires
non disponible

ID secondaires
non disponible

Résultats-Données individuelles des participants
non disponible

Informations complémentaires sur l'essai
non disponible

Résultats de l'essai

Résumé des résultats

non disponible

Lien vers les résultats dans le registre primaire

non disponible